Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

T. Bell, J. P. Crown, I. Láng, H. Bhattacharyya, G. Zanotti, S. Randolph, S. Kim, X. Huang, C. Huang Bartlett, R. S. Finn, D. Slamon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. This report assesses the impact of palbociclib in combination with letrozole versus letrozole alone on patient-reported outcomes of pain.Methods Palbociclib was evaluated in an open-label, randomized, phase II study (PALOMA-1/TRIO-18) among postmenopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic treatment for their advanced disease. Patients received continuous oral letrozole 2.5 mg daily alone or the same letrozole dose and schedule plus oral palbociclib 125 mg, given once daily for 3 weeks followed by 1 week off over repeated 28-day cycles. The primary study endpoint was investigator-assessed progression-free survival in the intent-to-treat population, and these results have recently been published (Finn et al., Lancet Oncol 2015;16:25-35). One of the key secondary endpoints was the evaluation of pain, as measured using the Brief Pain Inventory (BPI) patient-reported outcome tool. The BPI was administered at baseline and on day 1 of every cycle thereafter until disease progression and/or treatment discontinuation.Clinical trial registration This study is registered with ClinicalTrials.gov (NCT00721409).Results There were no statistically significant differences in Pain Severity or Pain Interference scores of the BPI between the two treatment groups for the overall population or among those with any bone disease at baseline. A limitation of the study is that results were not adjusted for the concomitant use of opioids or other medications used to control pain.Conclusions The addition of palbociclib to letrozole was associated with increased efficacy without negatively impacting pain severity or pain interference with daily activities.

Original languageEnglish
Pages (from-to)959-965
Number of pages7
JournalCurrent Medical Research and Opinion
Volume32
Issue number5
DOIs
Publication statusPublished - May 3 2016

Fingerprint

letrozole
Estrogen Receptors
Breast Neoplasms
Pain
Therapeutics
Equipment and Supplies
palbociclib
human ERBB2 protein

Keywords

  • Breast cancer
  • CDK 4/6
  • Cyclin-dependent kinases 4/6
  • ER+
  • Estrogen receptorpositive
  • Palbociclib
  • Patientreported outcomes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment. / Bell, T.; Crown, J. P.; Láng, I.; Bhattacharyya, H.; Zanotti, G.; Randolph, S.; Kim, S.; Huang, X.; Huang Bartlett, C.; Finn, R. S.; Slamon, D.

In: Current Medical Research and Opinion, Vol. 32, No. 5, 03.05.2016, p. 959-965.

Research output: Contribution to journalArticle

@article{deb09ca1066444d2be1d9cd92fd6437a,
title = "Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment",
abstract = "Background Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. This report assesses the impact of palbociclib in combination with letrozole versus letrozole alone on patient-reported outcomes of pain.Methods Palbociclib was evaluated in an open-label, randomized, phase II study (PALOMA-1/TRIO-18) among postmenopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic treatment for their advanced disease. Patients received continuous oral letrozole 2.5 mg daily alone or the same letrozole dose and schedule plus oral palbociclib 125 mg, given once daily for 3 weeks followed by 1 week off over repeated 28-day cycles. The primary study endpoint was investigator-assessed progression-free survival in the intent-to-treat population, and these results have recently been published (Finn et al., Lancet Oncol 2015;16:25-35). One of the key secondary endpoints was the evaluation of pain, as measured using the Brief Pain Inventory (BPI) patient-reported outcome tool. The BPI was administered at baseline and on day 1 of every cycle thereafter until disease progression and/or treatment discontinuation.Clinical trial registration This study is registered with ClinicalTrials.gov (NCT00721409).Results There were no statistically significant differences in Pain Severity or Pain Interference scores of the BPI between the two treatment groups for the overall population or among those with any bone disease at baseline. A limitation of the study is that results were not adjusted for the concomitant use of opioids or other medications used to control pain.Conclusions The addition of palbociclib to letrozole was associated with increased efficacy without negatively impacting pain severity or pain interference with daily activities.",
keywords = "Breast cancer, CDK 4/6, Cyclin-dependent kinases 4/6, ER+, Estrogen receptorpositive, Palbociclib, Patientreported outcomes",
author = "T. Bell and Crown, {J. P.} and I. L{\'a}ng and H. Bhattacharyya and G. Zanotti and S. Randolph and S. Kim and X. Huang and {Huang Bartlett}, C. and Finn, {R. S.} and D. Slamon",
year = "2016",
month = "5",
day = "3",
doi = "10.1185/03007995.2016.1157060",
language = "English",
volume = "32",
pages = "959--965",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

AU - Bell, T.

AU - Crown, J. P.

AU - Láng, I.

AU - Bhattacharyya, H.

AU - Zanotti, G.

AU - Randolph, S.

AU - Kim, S.

AU - Huang, X.

AU - Huang Bartlett, C.

AU - Finn, R. S.

AU - Slamon, D.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Background Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. This report assesses the impact of palbociclib in combination with letrozole versus letrozole alone on patient-reported outcomes of pain.Methods Palbociclib was evaluated in an open-label, randomized, phase II study (PALOMA-1/TRIO-18) among postmenopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic treatment for their advanced disease. Patients received continuous oral letrozole 2.5 mg daily alone or the same letrozole dose and schedule plus oral palbociclib 125 mg, given once daily for 3 weeks followed by 1 week off over repeated 28-day cycles. The primary study endpoint was investigator-assessed progression-free survival in the intent-to-treat population, and these results have recently been published (Finn et al., Lancet Oncol 2015;16:25-35). One of the key secondary endpoints was the evaluation of pain, as measured using the Brief Pain Inventory (BPI) patient-reported outcome tool. The BPI was administered at baseline and on day 1 of every cycle thereafter until disease progression and/or treatment discontinuation.Clinical trial registration This study is registered with ClinicalTrials.gov (NCT00721409).Results There were no statistically significant differences in Pain Severity or Pain Interference scores of the BPI between the two treatment groups for the overall population or among those with any bone disease at baseline. A limitation of the study is that results were not adjusted for the concomitant use of opioids or other medications used to control pain.Conclusions The addition of palbociclib to letrozole was associated with increased efficacy without negatively impacting pain severity or pain interference with daily activities.

AB - Background Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. This report assesses the impact of palbociclib in combination with letrozole versus letrozole alone on patient-reported outcomes of pain.Methods Palbociclib was evaluated in an open-label, randomized, phase II study (PALOMA-1/TRIO-18) among postmenopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic treatment for their advanced disease. Patients received continuous oral letrozole 2.5 mg daily alone or the same letrozole dose and schedule plus oral palbociclib 125 mg, given once daily for 3 weeks followed by 1 week off over repeated 28-day cycles. The primary study endpoint was investigator-assessed progression-free survival in the intent-to-treat population, and these results have recently been published (Finn et al., Lancet Oncol 2015;16:25-35). One of the key secondary endpoints was the evaluation of pain, as measured using the Brief Pain Inventory (BPI) patient-reported outcome tool. The BPI was administered at baseline and on day 1 of every cycle thereafter until disease progression and/or treatment discontinuation.Clinical trial registration This study is registered with ClinicalTrials.gov (NCT00721409).Results There were no statistically significant differences in Pain Severity or Pain Interference scores of the BPI between the two treatment groups for the overall population or among those with any bone disease at baseline. A limitation of the study is that results were not adjusted for the concomitant use of opioids or other medications used to control pain.Conclusions The addition of palbociclib to letrozole was associated with increased efficacy without negatively impacting pain severity or pain interference with daily activities.

KW - Breast cancer

KW - CDK 4/6

KW - Cyclin-dependent kinases 4/6

KW - ER+

KW - Estrogen receptorpositive

KW - Palbociclib

KW - Patientreported outcomes

UR - http://www.scopus.com/inward/record.url?scp=84964713774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964713774&partnerID=8YFLogxK

U2 - 10.1185/03007995.2016.1157060

DO - 10.1185/03007995.2016.1157060

M3 - Article

C2 - 26894413

AN - SCOPUS:84964713774

VL - 32

SP - 959

EP - 965

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -